Ian J Neeland

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 22

Top Topics

Particulate Matter

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Circulation. Cardiovascular quality and outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Sanjay Rajagopalan, Armando Vergara-Martel, Jeffrey Zhong, Haitham Khraishah, Mikhail Naum Kosiborod, Ian J Neeland, Jean-Eudes Dazard, Zhuo Chen, Thomas Munzel, Robert D Brook, Mark Nieuwenhuijsen, Peter Hovmand, Sadeer G Al-Kindi
The Urban Environment and Cardiometabolic Health. Circulation 149 (16) (2024)
Joseph Reed, Tony Dong, Elke Eaton, Janice Friswold, Jodie Porges, Sadeer G Al-Kindi, Sanjay Rajagopalan, Ian J Neeland
Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Diabetes, obesity & metabolism (2024)
Joseph Reed, Tony Dong, Elke Eaton, Janice Friswold, Jodie Porges, Sadeer G Al-Kindi, Sanjay Rajagopalan, Ian J Neeland
Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial. Diabetes, obesity & metabolism 26 (7) (2024)
Naveed Sattar, Ian J Neeland, Darren K McGuire
Obesity and Cardiovascular Disease: A New Dawn. Circulation 149 (21) (2024)
Sanjay Rajagopalan, Armando Vergara-Martel, Jeffrey Zhong, Haitham Khraishah, Mikhail Naum Kosiborod, Ian J Neeland, Jean-Eudes Dazard, Zhuo Chen, Thomas Munzel, Robert D Brook, Mark Nieuwenhuijsen, Peter Hovmand, Sadeer G Al-Kindi
The Urban Environment and Cardiometabolic Health. Circulation 149 (16) (2024)
Ian J Neeland, Jennifer Linge, Andreas L Birkenfeld
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism (2024)
Ian J Neeland, Jennifer Linge, Andreas L Birkenfeld
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism (2024)
Sanjay Rajagopalan, Armando Vergara-Martel, Jeffrey Zhong, Haitham Khraishah, Mikhail Naum Kosiborod, Ian J Neeland, Jean-Eudes Dazard, Zhuo Chen, Thomas Munzel, Robert D Brook, Mark Nieuwenhuijsen, Peter Hovmand, Sadeer G Al-Kindi
The Urban Environment and Cardiometabolic Health. Circulation 149 (16) (2024)
Sanjay Rajagopalan, Armando Vergara-Martel, Jeffrey Zhong, Haitham Khraishah, Mikhail Naum Kosiborod, Ian J Neeland, Jean-Eudes Dazard, Zhuo Chen, Thomas Munzel, Robert D Brook, Mark Nieuwenhuijsen, Peter Hovmand, Sadeer G Al-Kindi
The Urban Environment and Cardiometabolic Health. Circulation 149 (16) (2024)
Sadiya S Khan, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Aditya L Surapaneni, Michael J Blaha, April P Carson, Alexander R Chang, Elizabeth L Ciemins, Alan S Go, Orlando M Gutiérrez, Shih-Jen Hwang, Simerjot Kaur Jassal, Csaba P Kovesdy, Donald M Lloyd-Jones, Michael G Shlipak, Latha P Palaniappan, Laurence S Sperling, Salim S Virani, Katherine R Tuttle, Ian J Neeland, Sheryl L Chow, Janani Rangaswami, Michael J Pencina, Chiadi E Ndumele, Josef Coresh, null null
Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations. Circulation (2023)
Ioannis Milioglou, Issam Motairek, Salil Vasudeo Deo, Ravi Ramani, Ian J Neeland, Sanjay Rajagopalan, Sadeer G Al-Kindi
Time-Varying Cardiovascular Outcomes of Sodium-Glucose Cotransporter Inhibitors in Patients With Type 2 Diabetes: A Post Hoc Analysis of Pivotal Trials Using Restricted Mean Survival Time. Circulation. Cardiovascular quality and outcomes (2023)
Puneet S Kang, Ian J Neeland
Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update. Current cardiology reports (2023)
Ioannis Milioglou, Issam Motairek, Salil Vasudeo Deo, Ravi Ramani, Ian J Neeland, Sanjay Rajagopalan, Sadeer G Al-Kindi
Time-Varying Cardiovascular Outcomes of Sodium-Glucose Cotransporter Inhibitors in Patients With Type 2 Diabetes: A Post Hoc Analysis of Pivotal Trials Using Restricted Mean Survival Time. Circulation. Cardiovascular quality and outcomes 16 (3) (2023)
Ioannis Milioglou, Issam Motairek, Salil Vasudeo Deo, Ravi Ramani, Ian J Neeland, Sanjay Rajagopalan, Sadeer G Al-Kindi
Time-Varying Cardiovascular Outcomes of Sodium-Glucose Cotransporter Inhibitors in Patients With Type 2 Diabetes: A Post Hoc Analysis of Pivotal Trials Using Restricted Mean Survival Time. Circulation. Cardiovascular quality and outcomes 16 (3) (2023)
Ian J Neeland, Sadeer G Al-Kindi, Nour Tashtish, Elke Eaton, Janice Friswold, Sara Rahmani, Khendi T White-Solaru, Imran Rashid, Diamond Berg, Mariam Rana, Claire Sullivan, Betul Hatipoglu, Peter Pronovost, Sanjay Rajagopalan
Lessons Learned From a Patient-Centered, Team-Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program. Journal of the American Heart Association 11 (15) (2022)
Kershaw V Patel, Matthew W Segar, Carl J Lavie, Nitin Kondamudi, Ian J Neeland, Jaime P Almandoz, Corby K Martin, Salvatore Carbone, Javed Butler, Tiffany M Powell-Wiley, Ambarish Pandey
Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. Circulation (2021)
Ian J Neeland, Takatoshi Kasai, Catherine M Viscoli, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen, null null
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015. Diabetes care 44 (6) (2021)
Marat Fudim, Lin Zhong, Kershaw V Patel, Rohan Khera, Manal F Abdelmalek, Anna Mae Diehl, Robert W McGarrah, Jeroen Molinger, Cynthia A Moylan, Vishal Narasinga Rao, Kara Wegermann, Ian J Neeland, Ethan A Halm, Sandeep R Das, Ambarish Pandey
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. Journal of the American Heart Association 10 (22) (2021)
Christopher W Puleo, Colby R Ayers, Sonia Garg, Ian J Neeland, Alana A Lewis, Ambarish Pandey, Mark H Drazner, James A de Lemos
Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study). Biomarkers in medicine 15 (16) (2021)
Ian J Neeland, Darren K McGuire, Naveed Sattar
Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention? Circulation 144 (17) (2021)
Ian J Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Colby R Ayers, Craig R Malloy, Eunsook S Jin
Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial. Obesity (Silver Spring, Md.) 28 (7) (2020)
Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Catherine M Viscoli, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi, Odd Erik Johansen, null null
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes care 43 (12) (2020)